Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 1 - 25 of 673 Clear search
Zyme Communications
Fraser Murray, PhD, CEO, Pheno Therapeutics
Healthcare and Life Science 18 Nov 2026

Pheno Therapeutics granted two key patents protecting its selective GPR17 antagonist pipeline targeting neurological diseases

Patents cover a polymorph (crystalline form) of PTD802, Pheno's lead clinical candidate, and a composition of matter covering PTD939, Pheno's second GPR17 antagonist PTD802, a small molecule therapeutic designed to promote remyelination in neurological and neu
Zyme Communications
Calla Lily Clinical Care Co-Founders, Thang Vo-Ta, CEO, and Dr. Lara Zibners, Chairman
Healthcare and Life Science 17 Nov 2026

Calla Lily Clinical Care awarded Innovate UK grant to expand Callavid platform for vaginal microbiome health

£700k Growth Catalyst award supports adaptation of Callavid intravaginal drug delivery platform for live biotherapeutic products and probioticsProgramme addresses pressing need for new approaches to vaginal dysbiosis conditions and supports efforts to tackle antimicrobi
Zyme Communications
Enterprise Therapeutics logo
Healthcare and Life Science 17 Nov 2026

Enterprise Therapeutics granted EMA orphan medicinal product designation for novel cystic fibrosis therapy, ETD001

Investigational inhaled ENaC blocker developed to treat people with cystic fibrosis not benefitting from CFTR modulatorsPositive opinion recognises potential of ETD001 in treating rare and severe diseaseDecision follows successful Phase 2 clinical tria
Zyme Communications
Dr Nicki Thompson, CEO, TRIMTECH Therapeutics
Healthcare and Life Science 16 Nov 2026

TRIMTECH Therapeutics enters strategic research collaboration with Biogen to advance small molecule degraders for neurodegenerative disease

Collaboration with Biogen will leverage TRIMTECH’s proprietary TRIM21-based targeted protein degradation technology to develop novel protein degrading therapeutics for neurodegenerative diseases.Includes up to $32 million in upfront and research milestone payments, with
Zyme Communications
Laverock Therapeutics
Healthcare and Life Science 16 Nov 2026

Laverock Therapeutics appoints Parker Moss as Chief Executive Officer and Paul J. Sekhri as Executive Chairman

Appointment of experienced transatlantic leadership team, based in London and New York, to support lead programmes’ progression into the clinicInterim Chair Lisa Deschamps to transition to Non-Executive Director roleDavid Venables will step down as Chi
Zyme Communications
Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital	Dr Simon Williams,  General Manager, PlaqueTec
Healthcare and Life Science 12 Nov 2026

PlaqueTec’s BIOPATTERN trial passes 100 patients and expands to 8 NHS centres

PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centre

Zyme Communications
Barton House, Abingdon Science Park
Healthcare and Life Science 11 Nov 2026

T-Cypher Bio extends footprint in purpose-built laboratory space at Abingdon Science Park, Oxford

Newly built facility delivered by Kadans Science Partner at Barton House will support company growth and progression of novel T cell engager pipeline programmes

Zyme Communications
Dr. Jonathan Appleby Chief Scientific Officer, Mogrify  and Joe Foster Chief Executive Officer, Mogrify
Healthcare and Life Science 11 Nov 2026

Mogrify to present preclinical proof-of-concept data for first-in-class retinal in vivo reprogramming therapy

Preclinical proof-of-concept data will be presented at the FLORetina-ICOOR 2026 Congress, taking place from 3 - 6 December 2026Data demonstrate that MOGRIFY-derived transcription factors can preserve and restore functional vision in a rodent model of photoreceptor degen
Zyme Communications
The Lab Thread Research Lab Management Software
Healthcare and Life Science 10 Nov 2026

Lab Thread launches new AI tools and strengthens platform with universal AI assistant compatibility

· New MCP server connects external AI tools directly to structured laboratory data, with no exports or custom integrations required

· Suite of AI functions address key data bottlenecks in biological research labs, from protocol writing to equipment set-up

Zyme Communications
Stuart Rose, CEO, BioUK Neil Roberts, MD, SEHTA
Healthcare and Life Science 09 Nov 2026

BioUK acquires certain key assets of SEHTA to strengthen support for life science SMEs across the UK

Asset acquisition combines BioUK’s strength in biotech and therapeutics with SEHTA’s MedTech and HealthTech expertise, covering the full breadth of life science SMEsEnhances BioUK’s support offerings with SEHTA’s broad membership network and competencies in market acces
Zyme Communications
Edward Bruce-White, CEO, Combat Medical	Professor Joost Boormans, MD, PhD, Head of the Department of Urology, Erasmus MC
Healthcare and Life Science 09 Nov 2026

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

Retrospective study evaluated the efficacy and safety of HIVEC® with mitomycin C in patients treated at the Erasmus Medical Center and Amphia hospital between 2015 and 2022Real-world data support HIVEC® as a bladder-preserving alternative to radica
Zyme Communications
Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics
Healthcare and Life Science 09 Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight’s Fibr8 model to provide structural assessment as secondary endpoint in Contineum’s Phase 2 PROPEL-IPF clinical trial examining the safety and efficacy of PIPE-791 in idiopathic pulmonary fibrosis (IPF) patientsAnnouncement comes after a recent European Respira
Zyme Communications
logo
Healthcare and Life Science 05 Nov 2026

Amphista Therapeutics to present AMX-883 data at American Society of Hematology (ASH) Annual Meeting

AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and prel
Zyme Communications
QX Continuum™ and QX700™ ddPCR™ instrument family
Healthcare and Life Science 03 Nov 2026

Bio-Rad expands Precision Oncology Research Portfolio for Advanced Molecular Analysis Workflows

Expanded Portfolio Includes New Droplet Digital™ PCR Assays, Reagents and Technologies to Support Oncology Research Applications and Extend the Capabilities of the QX700™ ddPCR™ Systems

Zyme Communications
Dr Simon Walsh, CSO, Qureight
Healthcare and Life Science 02 Nov 2026

Qureight publishes in the European Respiratory Journal, calling for fibrosis burden to become the principal structural imaging biomarker for antifibrotic trials

Peer-reviewed Viewpoint ‘Fibrosis extent on HRCT: the principal structural imaging biomarker for antifibrotic trials’ presents argument for measuring both lung function and fibrosis extent in antifibrotic trialsEvaluation of evidence from multiple studies positions fibr
Zyme Communications
Pluto Workstation
Healthcare and Life Science 30 Oct 2026

Curiox Biosystems strengthens commercial leadership to expand adoption of centrifuge-free sample preparation

Curiox Biosystems Inc (Curiox), a provider of centrifuge-free (C-FREE™) sample preparation technologies for reproducible, automated flow cytometry workflows, today announced the expansion of its senior commercial team and the formation of a Strategic Advisory Board (SAB).

Zyme Communications
Atelerix logo
Healthcare and Life Science, Science and Engineering 27 Oct 2026

Atelerix and Frontier Space partner to enable biological sample preservation for space missions

Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced a partnership with Frontier Space, a UK based space biotechnology company building platform technology for in-orbit R&D and biomanufact

Zyme Communications
 Winners of the BioUK Awards 2026
Healthcare and Life Science 22 Oct 2026

BioUK Awards 2026 celebrate outstanding achievement and breakthrough innovations from across the Life Sciences

Abingdon, UK - BioUK, the not-for-profit membership organisation focused on catalysing success in UK life sciences, announces the winners of the 18th annual BioUK Awards following a ceremony hosted at the Royal Lancaster Hotel, London.

Zyme Communications
Opening of BioLabs | TUM. From left to right: Dr. Johannes Fruehauf, CEO BioLabs, Dr. Max Pöhlmann, Site Director, BioLabs TUM, Dr. Floris Engelhardt, CEO/CSO & Co-Founder Kano Therapeutics, Dr. Philipp Gerbert, CEO TUM Venture Labs, Johanna Michielin, Regional Director, BioLabs Europe
Healthcare and Life Science 21 Oct 2026

Eppendorf and BioLabs expand collaboration to support biotech innovation in Munich

•    The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies •    Builds on existing partnerships at BioLabs sites across the US, Germany and France

Zyme Communications
SPT Labtech’s firefly®+ 	Takara Bio’s SMART-Seq® mRNA LP
Healthcare and Life Science 20 Oct 2026

Takara Bio USA partners with SPT Labtech to deliver automation-ready NGS library preparation technologies

Trusted NGS chemistries from Takara Bio now optimized for firefly® automated workflows

Zyme Communications
 Dr. Adi Gilboa-Geffen, CEO of ScionxBio and  Dr. Yaniv Erlich, Chairman of the Board and co-founder of ScionxBio
Healthcare and Life Science 20 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA Therapeutics

Cambridge, UK, 20 October 2026: ScionxBio (the “company”, operating as a brand identity of Eleven Therapeutics Ltd.

Zyme Communications
Simon Walsh, CSO, Qureight
Healthcare and Life Science 20 Oct 2026

Qureight appointed imaging CRO for Phase 3 SURPASS-IPF trial as partnership with Celea Therapeutics expands

Celea has now contracted Qureight as the end-to-end imaging CRO for the phase 3 SURPASS-IPF trial, including Fibr8™ and four additional AI imaging models Joint poster at CHEST 2026 presents analysis completed as part of Qureight’s work on Celea’s phase 2b ELEVATE-I
Zyme Communications
Leading Life Science Organisations Collaborate for Second London Bio-Innovation Week
Healthcare and Life Science 14 Oct 2026

Leading life science organisations collaborate for second London Bio-Innovation Week

One Nucleus, SLAS, and ELRIG will connect their communities through cross-event networking and partnering opportunities during London Bio-Innovation Week
Zyme Communications
Dr. Yaniv Erlich, CEO and Co-Founder, Undecimal Bio, Shaul Ilan, COO and Co-Founder, Undecimal Bio
Healthcare and Life Science 13 Oct 2026

Undecimal Bio launches with $18 million oversubscribed Seed financing to address ‘liver trap’ in siRNA therapeutic delivery

·  A spin-out focused on AI-enabled decoding of the deliverome

·  Proprietary synthetic biology platform identifies conjugates that target RNA medicines beyond the liver, with initial focus on renovascular disease

Zyme Communications
Pierre Arsène, Founder and CEO, Mursla Bio	Dr Tomás Dias, CSO, Mursla Bio
Healthcare and Life Science 13 Oct 2026

Mursla Bio publishes peer-reviewed validation of Tissue-Specific Extracellular Vesicle Platform for Liquid Biopsy

Study published in Journal of Extracellular Vesicles validates platform for new class of liquid biopsy: multiomic disease biology of living cells from a chosen tissue, starting with the liver Platform underpins FDA Breakthrough Device-designated EvoLiver™ and preci

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS